Shattuck Labs, Inc. has dosed the first participants in a Phase 1 clinical trial of SL-325, a DR3 blocking antibody targeting TNF superfamily receptors. The company closed a private placement of up to $103 million in August 2025 to support the advancement of SL-325. Additionally, appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. were made to the Board of Directors. Financial results for the quarter ended September 30, 2025, show cash and cash equivalents of $86.1 million, with net loss of $10.1 million. Shattuck plans to attend upcoming investor conferences in December 2025.

SL-325, Shattuck’s lead product candidate, is a potential first-in-class DR3 antagonist antibody for the treatment of IBD and other inflammatory diseases. IND clearance for SL-325 occurred in August 2025, with the Phase 1 trial evaluating safety, tolerability, and PK in healthy volunteers. Shattuck also announced the appointment of industry experts to its Board of Directors. Financial guidance shows current cash and cash equivalents are expected to fund operations into 2029.

Shattuck Labs, Inc. is a biotechnology company specializing in the development of treatments for autoimmune and inflammatory diseases, with a focus on potential therapies for IBD. The company’s lead program, SL-325, is a DR3 antagonist antibody designed for a more complete blockade of the DR3/TL1A pathway. Financial statements as of September 30, 2025, show total assets of $100.3 million and liabilities of $7.1 million. Net loss for the quarter was $10.1 million, or $0.14 per share.

Read more at GlobeNewswire: Shattuck Labs Reports Third Quarter 2025 Financial Results